Skip to content

Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome

OnabotulinumtoxinA (Botox) Effect on Pain and Function in Recurrent Chronic Exertional Compartment Syndrome: a Pilot Study

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05006417
Enrollment
1
Registered
2021-08-16
Start date
2022-11-23
Completion date
2022-11-23
Last updated
2024-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compartment Syndrome of Leg

Brief summary

10 participants with Recurrent Chronic Exertional Compartment Syndrome (R-CECS) will be enrolled in a 6 month study at the University of Wisconsin Hospitals and Clinics to test the hypothesis that injection of Botox into the affected muscle group will alleviate pain associated with R-CECS.

Detailed description

Participants will be enrolled in study at initial clinic visit by study staff at which time diagnosis of R-CECS will be established based on elevated pressure measurements in patients who have had surgical release of the affected compartments. Pressure testing will be performed outside of the clinical study and will be required to establish the diagnosis of R-CECS. Initial clinic visit with study staff will consist of baseline measurements of ankle plantarflexion, dorsiflexion, inversion, and eversion strength using Kiio Force Sensor. The clinic visit with study staff will establish time point 0 and will consist of written consent for participation, Botox injection, and baseline University of Wisconsin Running Index (UWRI). Two months following this visit, the participant will have follow up with study staff. Study staff will again measure ankle strength (ankle inversion, eversion, plantarflexion, and dorsiflexion) using the Kiio Force Sensor utilizing the same strength assessment protocol. Study staff will monitor for side effects and administer the UWRI. Telephone follow up assessment of the UWRI will be made by study staff at 4 and 6 months.

Interventions

DRUGBotox

reconstituted at 100 units/mL, dosage will be based upon the affected muscles

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing to provide written informed consent * Willing to comply with all study procedures and be available for the duration of the study * Documented diagnosis of R-CECS determined with elevated compartmental pressure testing following lower extremity fascia release (fasciotomy or fasciectomy) * Females of childbearing potential must have a negative urine pregnancy test prior to enrollment and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy. * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Exclusion criteria

* History of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes * Known neuromuscular disease * Known pulmonary disease including but not limited to asthma, pneumonia, or upper respiratory tract infection * Dysphagia * Known cardiac disease including but not limited to congestive heart failure, arrhythmia, or history of myocardial infarction * Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to enrollment * Currently or have taken in the past medications that affect neuromuscular function, aminoglycosides, muscle relaxants, or other botulinum neurotoxin agents. Currently taking any blood-thinning medications including, but not limited to Plavix, Coumadin, Eliquis, Xarelto * Women who are pregnant or breast-feeding * Vulnerable populations * Not suitable for study participation due to other reasons at the discretion of the investigator

Design outcomes

Primary

MeasureTime frameDescription
Change in Pain Score2 months, 4 months, 6 monthsChange in pain score (0-10, where 10 is increased pain) will be assessed at each time point will be assessed at each time point (2, 4, 6 months) using Friedman's ANOVA.
Number of Participants With Lower Extremity Weaknessup to 6 monthsA primary safety endpoint is incidence of lower extremity weakness, measured by
Incidence of Adverse Eventsone study visit (within 2 hours)A primary safety endpoint is the incidence of adverse events, such as bruising, bleeding, pain, redness, or swelling where the injection was given.

Secondary

MeasureTime frameDescription
Change in Ankle Eversion Strength Using Kiio Force Sensorbaseline and month 2A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).
Change in Ability to Perform Activities of Daily Livingbaseline, 2 months, 4 months, 6 monthsA question on the University of Wisconsin Running Index (UWRI) asks the participant to indicate how their running injury impacts their ability to perform daily activities. The scoring is on a 5 point likert scale from 0 = unable to perform, 1 = significantly impact, 2 = moderately impact, 3 = slightly impact, to 4 = no impact.
Participant Frustration With Injurybaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate how frustrated they are by their running injury. The scoring is on a 5 point likert scale from 0 = extremely frustrated, 1 = significantly frustrated, 2 = moderately frustrated, 3 = mildly frustrated, to 4 = not frustrated.
Participant Perception of Recovery From Injurybaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate how much recovery have they made from their running injury. The scoring is on a 5 point likert scale from 0 = no recovery, 1 = minimal recovery, 2 = moderate recovery, 3 = significant recovery, to 4 = complete recovery.
Change in Ankle Dorsiflexion Strength Using Kiio Force Sensorbaseline and month 2A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).
Change in Running Duration: Weeklybaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate if their weekly mileage or weekly running time changed as a result of their injury. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significantly reduced, 2 = moderately reduced, 3 = minimally reduced, to 4 = same or greater than before my injury.
Change in Running Duration: Longest Runbaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate if the distance of their longest weekly run has changed as a result of their injury. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significantly reduced, 2 = moderately reduced, 3 = minimally reduced, to 4 = same or longer than before my injury.
Change in Running Speedbaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate if the distance of their longest weekly run has changed as a result of their injury. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significantly reduced, 2 = moderately reduced, 3 = minimally reduced, to 4 = same or longer than before my injury.
Participant Confidence in Increasing the Duration and Intensity of Runningbaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate how their injury affects their confidence to increase the duration or intensity of their running. The scoring is on a 5 point likert scale from 0 = I cannot increase my running, 1 = if I increase, I might get worse, 2 = neutral, 3 = if I increase I might be fine, to 4 = confident to increase my running.
Pain in the 24 Hours Following Runningbaseline, 2 months, 4 months, 6 monthsA question on the UWRI asks the participant to indicate how much pain they experience during the 24 hours following a run. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significant pain, 2 = moderate pain, 3 = minimal pain, to 4 = no pain.
Change in Ankle Plantarflexion Strength Using Kiio Force Sensorbaseline and month 2A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).
Change in Ankle Inversion Strength Using Kiio Force Sensorbaseline and month 2A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).

Countries

United States

Participant flow

Recruitment details

One participant was enrolled in November of 2022

Participants by arm

ArmCount
Participants With R-CECS
Botox to be injected under standard palpatory technique into the affected lower leg compartment. Botox: reconstituted at 100 units/mL, dosage will be based upon the affected muscles
1
Total1

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPI terminated study for problems with strength testing equipment1

Baseline characteristics

CharacteristicParticipants With R-CECS
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
1 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
1 Participants
Region of Enrollment
United States
1 participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 1
other
Total, other adverse events
0 / 1
serious
Total, serious adverse events
0 / 1

Outcome results

Primary

Change in Pain Score

Change in pain score (0-10, where 10 is increased pain) will be assessed at each time point will be assessed at each time point (2, 4, 6 months) using Friedman's ANOVA.

Time frame: 2 months, 4 months, 6 months

Population: only baseline data collected before study was terminated

ArmMeasureGroupValue
UnknownChange in Pain Score2 months
UnknownChange in Pain Score4 months
UnknownChange in Pain Score6 months
Primary

Incidence of Adverse Events

A primary safety endpoint is the incidence of adverse events, such as bruising, bleeding, pain, redness, or swelling where the injection was given.

Time frame: one study visit (within 2 hours)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Participants With R-CECS - Left LegIncidence of Adverse Events0 Participants
Primary

Number of Participants With Lower Extremity Weakness

A primary safety endpoint is incidence of lower extremity weakness, measured by

Time frame: up to 6 months

Population: study terminated early

Secondary

Change in Ability to Perform Activities of Daily Living

A question on the University of Wisconsin Running Index (UWRI) asks the participant to indicate how their running injury impacts their ability to perform daily activities. The scoring is on a 5 point likert scale from 0 = unable to perform, 1 = significantly impact, 2 = moderately impact, 3 = slightly impact, to 4 = no impact.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Ability to Perform Activities of Daily Livingbaseline2 score on a scale
Secondary

Change in Ankle Dorsiflexion Strength Using Kiio Force Sensor

A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).

Time frame: baseline and month 2

Population: strength equipment not functional, study terminated as a result

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Ankle Dorsiflexion Strength Using Kiio Force Sensorbaseline24.9 pounds of force
Participants With R-CECS - Right LegChange in Ankle Dorsiflexion Strength Using Kiio Force Sensorbaseline25.2 pounds of force
Secondary

Change in Ankle Eversion Strength Using Kiio Force Sensor

A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).

Time frame: baseline and month 2

Population: strength equipment not functional, study terminated as a result

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Ankle Eversion Strength Using Kiio Force Sensorbaseline22.7 pounds of force
Participants With R-CECS - Right LegChange in Ankle Eversion Strength Using Kiio Force Sensorbaseline22.8 pounds of force
Secondary

Change in Ankle Inversion Strength Using Kiio Force Sensor

A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).

Time frame: baseline and month 2

Population: strength equipment not functional, study terminated as a result

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Ankle Inversion Strength Using Kiio Force Sensorbaseline22.9 pounds of force
Participants With R-CECS - Right LegChange in Ankle Inversion Strength Using Kiio Force Sensorbaseline22.8 pounds of force
Secondary

Change in Ankle Plantarflexion Strength Using Kiio Force Sensor

A Kiio Force Sensor will be used to measure the change in ankle strength. Change in strength outcomes at baseline and 2 months will be assessed using Wilcoxon signed rank tests or, if necessary, linear mixed effects models for repeated measures, to account for intra-subject correlation (left and right legs).

Time frame: baseline and month 2

Population: strength equipment not functional, study terminated as a result

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Ankle Plantarflexion Strength Using Kiio Force Sensorbaseline154.3 pounds of force
Participants With R-CECS - Right LegChange in Ankle Plantarflexion Strength Using Kiio Force Sensorbaseline156.4 pounds of force
Secondary

Change in Running Duration: Longest Run

A question on the UWRI asks the participant to indicate if the distance of their longest weekly run has changed as a result of their injury. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significantly reduced, 2 = moderately reduced, 3 = minimally reduced, to 4 = same or longer than before my injury.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Running Duration: Longest Runbaseline0 score on a scale
Secondary

Change in Running Duration: Weekly

A question on the UWRI asks the participant to indicate if their weekly mileage or weekly running time changed as a result of their injury. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significantly reduced, 2 = moderately reduced, 3 = minimally reduced, to 4 = same or greater than before my injury.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Running Duration: Weeklybaseline0 score on a scale
Secondary

Change in Running Speed

A question on the UWRI asks the participant to indicate if the distance of their longest weekly run has changed as a result of their injury. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significantly reduced, 2 = moderately reduced, 3 = minimally reduced, to 4 = same or longer than before my injury.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegChange in Running Speedbaseline0 score on a scale
Secondary

Pain in the 24 Hours Following Running

A question on the UWRI asks the participant to indicate how much pain they experience during the 24 hours following a run. The scoring is on a 5 point likert scale from 0 = unable to run, 1 = significant pain, 2 = moderate pain, 3 = minimal pain, to 4 = no pain.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegPain in the 24 Hours Following Runningbaseline0 score on a scale
Secondary

Participant Confidence in Increasing the Duration and Intensity of Running

A question on the UWRI asks the participant to indicate how their injury affects their confidence to increase the duration or intensity of their running. The scoring is on a 5 point likert scale from 0 = I cannot increase my running, 1 = if I increase, I might get worse, 2 = neutral, 3 = if I increase I might be fine, to 4 = confident to increase my running.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegParticipant Confidence in Increasing the Duration and Intensity of Runningbaseline0 score on a scale
Secondary

Participant Frustration With Injury

A question on the UWRI asks the participant to indicate how frustrated they are by their running injury. The scoring is on a 5 point likert scale from 0 = extremely frustrated, 1 = significantly frustrated, 2 = moderately frustrated, 3 = mildly frustrated, to 4 = not frustrated.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegParticipant Frustration With Injurybaseline0 score on a scale
Secondary

Participant Perception of Recovery From Injury

A question on the UWRI asks the participant to indicate how much recovery have they made from their running injury. The scoring is on a 5 point likert scale from 0 = no recovery, 1 = minimal recovery, 2 = moderate recovery, 3 = significant recovery, to 4 = complete recovery.

Time frame: baseline, 2 months, 4 months, 6 months

Population: study was terminated after baseline measure

ArmMeasureGroupValue (NUMBER)
Participants With R-CECS - Left LegParticipant Perception of Recovery From Injurybaseline0 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026